Skye Bioscience, Inc.
جودة البيانات: 83%
SKYE
NASDAQ
Manufacturing
Chemicals
KWD 0.72
▼
KWD 0.01
(-0.80%)
القيمة السوقية: 24.20 M
السعر
KWD 0.73
القيمة السوقية
24.20 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Negative free cash flow of -43.07 M
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-146.18%
أقل من متوسط القطاع (-54.47%)
ROIC-119.65%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio4.77
Interest CoverageN/A
التقييم
PE (TTM|NTM)
-0.43 | -0.67
أعلى من متوسط القطاع (-1.49)
P/B Ratio0.74
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -0.4 | -1.5 |
| P/B | 0.7 | 1.6 |
| ROE % | -146.2 | -54.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.9 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
8 محللين
Buy
الحالي
KWD 0.72
المستهدف
KWD 8.25
KWD 2.00
KWD 7.50
KWD 20.00
التوقعات
مكرر الربحية المستقبلي
-0.67
ربحية السهم المستقبلية
-KWD 1.07
الإيرادات المقدّرة
0.0
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 1.07
-KWD 1.39 – -KWD 0.63
|
0.0 | 3 |
| FY2026 |
-KWD 1.05
-KWD 1.44 – -KWD 0.70
|
0.0 | 5 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.25
-KWD 0.36 – -KWD 0.14
|
0.0 | 5 |
| 2026 Q1 |
-KWD 0.33
-KWD 0.51 – -KWD 0.18
|
0.0 | 5 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.31 | -KWD 0.37 | -20.2% |
| Q32025 | -KWD 0.32 | -KWD 0.32 | -1.2% |
| Q22025 | -KWD 0.30 | -KWD 0.45 | -48.9% |
| Q12025 | -KWD 0.29 | -KWD 0.28 | +3.5% |
ETFs Holding This Stock
BRSIX
BRSIX
0.07% weight
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -55.92 M |
| ROE | -146.18% | ROA | -119.64% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -43.07 M |
| ROIC | -119.65% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 4.77 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 31.56 M | Tangible Book Value | 32.84 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.43 | Forward P/E | -0.67 |
| P/B Ratio | 0.74 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -177.97% | ||
| Market Cap | 24.20 M | Enterprise Value | 5.76 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.41 | Revenue / Share | N/A |
| FCF / Share | -1.29 | OCF / Share | -1.29 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 77.01% |
| SBC-Adj. FCF | -51.14 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -55.92 M | -26.57 M | -37.64 M | -19.48 M | -8.52 M |
| EPS (Diluted) | -1.41 | -0.73 | -5.37 | -0.04 | -0.02 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -58.16 M | -30.19 M | -34.74 M | -18.31 M | -7.85 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | 6.01 M | 2.93 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 723,352.0 | 298,640.0 | — | — | — |
| Interest Expense | 0.0 | 749,308.0 | 906,270.0 | 665,133.0 | 769,159.0 |
| Income Tax | 5,400.0 | 10,071.0 | 3,600.0 | 6,741.0 | 2,100.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 28.31 M | 72.76 M | 11.94 M | 9.11 M | 9.86 M |
| Total Liabilities | 8.29 M | 4.61 M | 14.07 M | 12.12 M | 3.99 M |
| Shareholders' Equity | 20.02 M | 68.15 M | -2.13 M | -3.01 M | 5.86 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 5.88 M | 68.42 M | — | — | — |
| Current Assets | 27.09 M | 70.83 M | 11.65 M | 8.94 M | 9.61 M |
| Current Liabilities | 8.21 M | 4.34 M | 13.90 M | 12.12 M | 3.91 M |
{"event":"ticker_viewed","properties":{"ticker":"SKYE","listing_kind":"stock","pathname":"/stocks/skye","exchange":"NASDAQ","country":"US"}}